Charles Schwab Investment Management Inc. Buys 15,042 Shares of Inspire Medical Systems, Inc. (NYSE:INSP)

Charles Schwab Investment Management Inc. increased its position in Inspire Medical Systems, Inc. (NYSE:INSP - Free Report) by 5.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 296,207 shares of the company's stock after buying an additional 15,042 shares during the period. Charles Schwab Investment Management Inc. owned about 0.99% of Inspire Medical Systems worth $54,911,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the company. First Horizon Advisors Inc. increased its stake in shares of Inspire Medical Systems by 885.7% during the 4th quarter. First Horizon Advisors Inc. now owns 138 shares of the company's stock valued at $26,000 after acquiring an additional 124 shares during the last quarter. True Wealth Design LLC purchased a new stake in shares of Inspire Medical Systems during the 3rd quarter worth about $30,000. Farther Finance Advisors LLC lifted its position in Inspire Medical Systems by 1,158.3% during the third quarter. Farther Finance Advisors LLC now owns 151 shares of the company's stock valued at $32,000 after buying an additional 139 shares in the last quarter. Smartleaf Asset Management LLC increased its position in shares of Inspire Medical Systems by 178.9% in the fourth quarter. Smartleaf Asset Management LLC now owns 357 shares of the company's stock worth $66,000 after acquiring an additional 229 shares in the last quarter. Finally, Nisa Investment Advisors LLC lifted its holdings in shares of Inspire Medical Systems by 37.3% during the 4th quarter. Nisa Investment Advisors LLC now owns 368 shares of the company's stock valued at $68,000 after acquiring an additional 100 shares in the last quarter. Hedge funds and other institutional investors own 94.91% of the company's stock.

Remove Ads

Insider Activity at Inspire Medical Systems

In other news, CTO John Rondoni sold 583 shares of the stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $170.49, for a total value of $99,395.67. Following the completion of the sale, the chief technology officer now directly owns 10,424 shares of the company's stock, valued at $1,777,187.76. This represents a 5.30 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Randy Ban sold 25,584 shares of the firm's stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $183.50, for a total transaction of $4,694,664.00. Following the sale, the insider now owns 7,259 shares of the company's stock, valued at approximately $1,332,026.50. This represents a 77.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 26,225 shares of company stock worth $4,806,530. 4.10% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the company. Piper Sandler decreased their price target on Inspire Medical Systems from $260.00 to $233.00 and set an "overweight" rating for the company in a report on Monday, February 10th. Truist Financial cut their price target on shares of Inspire Medical Systems from $250.00 to $235.00 and set a "buy" rating on the stock in a report on Tuesday, February 11th. Stifel Nicolaus decreased their price target on Inspire Medical Systems from $200.00 to $190.00 and set a "hold" rating for the company in a research note on Tuesday, January 21st. Wells Fargo & Company reduced their target price on Inspire Medical Systems from $198.00 to $195.00 and set an "equal weight" rating on the stock in a report on Tuesday, February 11th. Finally, KeyCorp reaffirmed an "overweight" rating and issued a $234.00 price target (down from $236.00) on shares of Inspire Medical Systems in a report on Friday, January 24th. Three research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, Inspire Medical Systems currently has an average rating of "Moderate Buy" and an average price target of $228.82.

Inspire Medical Systems Stock Performance

Shares of NYSE:INSP traded up $4.43 during trading hours on Monday, hitting $166.59. 299,181 shares of the company's stock traded hands, compared to its average volume of 580,922. The company's fifty day simple moving average is $184.92 and its two-hundred day simple moving average is $192.07. Inspire Medical Systems, Inc. has a 52 week low of $123.00 and a 52 week high of $257.40. The company has a market cap of $4.94 billion, a price-to-earnings ratio of 96.29, a price-to-earnings-growth ratio of 2.86 and a beta of 1.48.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last issued its quarterly earnings results on Monday, February 10th. The company reported $1.15 earnings per share for the quarter, topping analysts' consensus estimates of $0.74 by $0.41. Inspire Medical Systems had a return on equity of 8.19% and a net margin of 6.67%. On average, analysts anticipate that Inspire Medical Systems, Inc. will post 2.16 EPS for the current fiscal year.

Inspire Medical Systems Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.